SRC and lung cancer: The results indicated that the phosphorylation of Src Y418, EGFR Y1068 and STAT3 Y705 was reduced in a dose-dependent manner (50–500 nM) by digoxin in the A549 lung cancer cell line that possesses wild-type EGFR (Fig 3B).